Published in J Vasc Surg on January 01, 2005
Emerging lymphatic imaging technologies for mouse and man. J Clin Invest (2014) 1.06
Analysis of case series of milky urine: A single center and departmental clinical experience with emphasis on management perspectives: A prospective observational study. Urol Ann (2014) 0.86
Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI. Magn Reson Med (2015) 0.81
New diagnostic modalities in the evaluation of lymphedema. J Vasc Surg Venous Lymphat Disord (2017) 0.77
Lymphatic mapping and lymphedema surgery in the breast cancer patient. Gland Surg (2015) 0.77
Regarding "Noncontrast three-dimensional magnetic resonance imaging vs lymphoscintigraphy in the evaluation of lymph circulation disorders: a comparative study". J Vasc Surg (2005) 0.75
Primary lower limb lymphoedema: classification with non-contrast MR lymphography. Eur Radiol (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle (2010) 2.26
Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics (2005) 2.01
Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem (2005) 2.01
Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol (2006) 1.95
Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat Med (2011) 1.93
Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol (2006) 1.91
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle (2010) 1.89
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A (2009) 1.89
Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) (2010) 1.88
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol (2009) 1.87
Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle (2011) 1.82
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol (2004) 1.80
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol (2006) 1.75
Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell (2009) 1.68
Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res (2006) 1.64
ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest (2012) 1.62
Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle (2009) 1.61
Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res (2010) 1.55
Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J Clin Invest (2012) 1.52
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 1.48
DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem (2003) 1.47
Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res (2010) 1.45
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
Lasing in metal-insulator-metal sub-wavelength plasmonic waveguides. Opt Express (2009) 1.42
p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res (2002) 1.36
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol (2004) 1.34
Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem (2005) 1.33
Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle (2011) 1.32
microRNA, cell cycle, and human breast cancer. Am J Pathol (2010) 1.32
Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes. Bioinformatics (2009) 1.29
The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab (2009) 1.28
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci U S A (2010) 1.20
Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol (2006) 1.20
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res (2014) 1.19
Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry (2003) 1.19
Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther (2009) 1.18
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res (2010) 1.17
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res (2009) 1.14
PPARgamma activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol (2009) 1.14
The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem (2004) 1.14
ErbB2 induces Notch1 activity and function in breast cancer cells. Clin Transl Sci (2008) 1.13
BRCA1 inhibition of telomerase activity in cultured cells. Mol Cell Biol (2003) 1.12
Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation. Trends Endocrinol Metab (2007) 1.11
Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol (2009) 1.11
Bayesian model selection for incomplete data using the posterior predictive distribution. Biometrics (2012) 1.08
Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res (2013) 1.07
Effects of replacing the unreliable cDNA microarray measurements on the disease classification based on gene expression profiles and functional modules. Bioinformatics (2006) 1.07
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol (2009) 1.06
Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol (2009) 1.05
The functional significance of nuclear receptor acetylation. Steroids (2007) 1.04
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther (2002) 1.04
Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. Oncotarget (2013) 1.03
The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget (2014) 1.01
Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res (2010) 1.00
Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res (2013) 1.00
PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b. Cell Cycle (2011) 0.99
Globally predicting protein functions based on co-expressed protein-protein interaction networks and ontology taxonomy similarities. Gene (2006) 0.99
Nuclear receptor modifications and endocrine cell proliferation. J Steroid Biochem Mol Biol (2003) 0.99
Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle (2012) 0.97
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet (2012) 0.96
Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol (2013) 0.95
Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res (2013) 0.94
3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Mol Endocrinol (2005) 0.94
Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res (2009) 0.93
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle (2013) 0.93
ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem (2014) 0.92
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem (2008) 0.92
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget (2014) 0.92
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Nat Commun (2013) 0.91
Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J Pathol (2009) 0.91
Tumor-suppressive effects of CDK8 in endometrial cancer cells. Cell Cycle (2013) 0.90
A computational approach for functional mapping of quantitative trait loci that regulate thermal performance curves. PLoS One (2007) 0.90
Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. Cancer Res (2014) 0.90
Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting. J Biopharm Stat (2011) 0.88
Spatial composition grading of quaternary ZnCdSSe alloy nanowires with tunable light emission between 350 and 710 nm on a single substrate. ACS Nano (2010) 0.88
p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res (2006) 0.87
Acetylation in hormone signaling and the cell cycle. Cytokine Growth Factor Rev (2002) 0.87
Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products. J Nucl Med (2009) 0.87
Transcription elongation regulator 1 is a co-integrator of the cell fate determination factor Dachshund homolog 1. J Biol Chem (2010) 0.86
Comparison of different normalization assumptions for analyses of DNA methylation data from the cancer genome. Gene (2012) 0.86
Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol (2007) 0.85
Epigenetics and the estrogen receptor. Ann N Y Acad Sci (2006) 0.85
A causal model for joint evaluation of placebo and treatment-specific effects in clinical trials. Biometrics (2013) 0.84